Loading...
Pregnant and postpartum women are at excess risk for complications of SARS-CoV-2 infection, yet they were excluded from the Phase 3 clinical trials testing COVID-19 vaccine efficacy (although they are among those recommended via Emergency Use Authorization to receive the vaccines). Researchers in Israel evaluated the effectiveness of the Pfizer-BioNTech mRNA vaccine (BNT162b2) in a retrospective cohort of all pregnant women from a healthcare system representing 27% of the Israeli population. A total of 7530 women who were vaccinated were matched by calendar day to 7530 women who were not vaccinated; the primary outcome was SARS-CoV-2 infection 28 days after the first dose.
Beginning 28 days after the first dose (mean follow-up, 37 days), 10 …